Akt1&PKA-IN-2 ((R)-29), a compound with specificity towards PKB/AKT and notable selectivity for cyclin-dependent kinase 2 (CDK2), effectively inhibits AKT1, PKAa, and CDK2a with IC50 values of 0.007 µM, 0.01 µM, and 0.69 µM, respectively.